In recent years, studies have successively confirmed that the first and so far the only angiotensin receptor–neprilysin inhibitor (ARNI) sacubitril/valsartan can reduce blood pressure in patients with CKD more effectively than RAAS inhibitors and can improve the prognosis in patients with heart failure (24). This evidence concerns the gene MME and heart failure.